Syra Health Corp. Class A Common Stock
Price Action
Technical Summary
STAGE 2 UPTRENDSyra Health Corp. Class A Common Stock is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 99), indicating clear outperformance against the broad market. Earnings growth of 129% provides fundamental context to the price action. Investors should exercise caution due to high volatility (232% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.51 | +6.68% | ABOVE |
| 50 SMA | $0.48 | +12.12% | ABOVE |
| 100 SMA | $0.33 | +63.24% | ABOVE |
| 150 SMA | $0.25 | +118.00% | ABOVE |
| 200 SMA | $0.21 | +162.51% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SYRA in an uptrend right now?
SYRA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, SYRA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is SYRA overbought or oversold?
SYRA's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is SYRA outperforming the market?
SYRA has a Relative Strength (RS) Rating of 99 out of 99. Yes, SYRA is a market leader, outperforming 99% of all stocks over the past 12 months.
Where is SYRA in its 52-week range?
SYRA is trading at $0.54, which is 74% of its 52-week high ($0.73) and 72% above its 52-week low ($0.05).
How volatile is SYRA?
SYRA has a Beta of -0.61 and 52-week volatility of 232%. It's less volatile than the S&P 500 - generally more stable.